Get the Weekly Intelligence Brief — top committee picks every Sunday.
IQV · NYSE · STOCK

IQVIA (IQV) Stock Analysis

Healthcare Updated October 10, 2026
$259.81
52W $154.50 – $277.40
53/100
$42.78B
32.0
1.17
AI Committee Verdict
Watch
53/100
Conviction: Contested · 50% agreement · 6 analysts
-32.2%
Contested

Is IQV Bullish or Bearish?

Mixed. Innellis AI committee rates IQVIA (IQV) Watch with a composite score of 53/100 , based on 6 analysts with 50% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +6.53 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -13.47 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.31 across 13 articles, 14d). Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • ROE of 21.9% shows genuine earnings power backing the valuation — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • News sentiment is positive (+0.31 across 13 articles, 14d) — News
Bear Case
  • P/E of 31.4 is moderate-to-rich — Value
  • Price-to-book of 5.9x prices in significant intangible value — Value
  • Debt-to-equity of 2.45 adds balance-sheet risk to the value case — Value
  • MACD histogram negative -- bearish momentum — Technical
  • High leverage (debt-to-equity 2.45) amplifies downside in a stress scenario — Risk
  • Current ratio of 0.75 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 75%
of 192 Healthcare peers
Value Analyst neutral
45 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 21.9% shows genuine earnings power backing the valuation
− P/E of 31.4 is moderate-to-rich
Growth Analyst bullish
62 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst bearish
32 / 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.45) amplifies downside in a stress scenario
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
68 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.31 across 13 articles, 14d)
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 53.5 to 53.5.

Analyst-level changes:
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
41.6
Neutral
MACD Histogram
-2.100
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.18
Inside Bands
Price vs Moving Averages
EMA 9
$261.97 Below
EMA 21
$262.90 Below
EMA 50
$252.83 Above
EMA 200
$216.52 Above

Fundamental Analysis

Valuation
33
Growth
67
Profitability
50
Financial Health
0
Cash Flow
70
Valuation
P/E Ratio 32.0×
P/B Ratio 7.04×
PEG Ratio 1.94
Dividend Yield 0.00%
52W High $277.40
52W Low $154.50
Quality & Growth
ROE 2091.3%
ROA 454.2%
Gross Margin 2623.2%
Operating Margin 1357.2%
Revenue Growth YoY —
Debt / Equity 2.63
AI Fundamental Assessment
P/E ratio of 32.0 (rich relative to a 15-40x range); Price-to-book of 7.0x; PEG ratio of 1.9 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 20.9%; Return on assets of 4.5%; Net margin of 8.1%; Gross margin of 26.2%; Current ratio of 0.71 (tight short-term liquidity); Debt-to-equity of 2.63; Free cash flow per share is positive (15.63); Most recent quarter beat estimates by 2.9%; 2 consecutive earnings beats; EPS growth accelerating (-15.2% -> +8.6% QoQ); Average YoY EPS growth of 12.1%; Analyst estimates falling over recent quarters
Get the Full IQV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime